RISE: Adult medication
Update 06-10-2019 | RISE adult medication results highlight disparity with youth with diabetes
Presenters: Sharon Edelstein, ScM; Kieren J. Mather, MD; David A. Ehrmann, MD; Steven E. Kahn, MB, ChB; Sonia Caprio, MD; Thomas A. Buchanan, MD.
Sunday 9 June: 12:00–13:30
The first RISE consortium studies showed that early intensive treatment with metformin plus insulin did not slow the decline of beta-cell function in children with impaired glycemic regulation or recently diagnosed type 2 diabetes.
In the second study (BetaFat), perhaps surprisingly, the more radical approach of gastric banding failed to slow beta-cell decline in adults with prediabetes or early type 2 diabetes.
The third and final of the planned RISE studies, also in adults, compares the effects of placebo, metformin with or without liraglutide, and 3 months of upfront insulin followed by 9 months of metformin. Will the findings presented at ADA finally show some evidence that treatment intensity can actually influence the underlying disease pathogenesis?
- News story | RISE adult medication results highlight disparity with youth with diabetes
- News story | RISE: Early insulin does not slow beta cell decline in youth with type 2 diabetes
- External link | Published design of the RISE consortium studies
- Clinical trial commentary | WATCH: Dana Dabelea comments on the RISE findings
- News story | Gastric banding has little effect on beta-cell decline in early type 2 diabetes
- Clinical trial commentary | WATCH: John Wilding discusses the BetaFat study findings